Abstract
The host range of retroviral vectors including lentiviral vectors can be expanded or altered by a process known as pseudotyping. Pseudotyped lentiviral vectors consist of vector particles bearing glycoproteins (GPs) derived from other enveloped viruses. Such particles possess the tropism of the virus from which the GP was derived. For example, to exploit the natural neural tropism of rabies virus, vectors designed to target the central nervous system have been pseudotyped using rabies virus-derived GPs. Among the first and still most widely used GPs for pseudotyping lentiviral vectors is the vesicular stomatitis virus GP (VSV-G), due to the very broad tropism and stability of the resulting pseudotypes. Pseudotypes involving VSV-G have become effectively the standard for evaluating the efficiency of other pseudotypes. This review samples a few of the more prominent examples from the ever-expanding list of published lentiviral pseudotypes, noting comparisons made with pseudotypes involving VSV-G in terms of titer, viral particle stability, toxicity, and hostcell specificity. Particular attention is paid to publications of successfully targeting a specific organ or cell types.
Keywords: lentiviral vector, gene therapy, glycoproteins, vector tropism
Current Gene Therapy
Title: Altering the Tropism of Lentiviral Vectors through Pseudotyping
Volume: 5 Issue: 4
Author(s): James Cronin, Xian-Yang Zhang and Jakob Reiser
Affiliation:
Keywords: lentiviral vector, gene therapy, glycoproteins, vector tropism
Abstract: The host range of retroviral vectors including lentiviral vectors can be expanded or altered by a process known as pseudotyping. Pseudotyped lentiviral vectors consist of vector particles bearing glycoproteins (GPs) derived from other enveloped viruses. Such particles possess the tropism of the virus from which the GP was derived. For example, to exploit the natural neural tropism of rabies virus, vectors designed to target the central nervous system have been pseudotyped using rabies virus-derived GPs. Among the first and still most widely used GPs for pseudotyping lentiviral vectors is the vesicular stomatitis virus GP (VSV-G), due to the very broad tropism and stability of the resulting pseudotypes. Pseudotypes involving VSV-G have become effectively the standard for evaluating the efficiency of other pseudotypes. This review samples a few of the more prominent examples from the ever-expanding list of published lentiviral pseudotypes, noting comparisons made with pseudotypes involving VSV-G in terms of titer, viral particle stability, toxicity, and hostcell specificity. Particular attention is paid to publications of successfully targeting a specific organ or cell types.
Export Options
About this article
Cite this article as:
Cronin James, Zhang Xian-Yang and Reiser Jakob, Altering the Tropism of Lentiviral Vectors through Pseudotyping, Current Gene Therapy 2005; 5 (4) . https://dx.doi.org/10.2174/1566523054546224
DOI https://dx.doi.org/10.2174/1566523054546224 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Central Nervous System Agents in Medicinal Chemistry Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design Applications of Nanomaterials for Cancer Treatment: Recent Patents Review
Recent Patents on Nanomedicine Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression
Current Protein & Peptide Science Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Applications of Lentiviral Vectors for shRNA Delivery and Transgenesis
Current Gene Therapy The Immune System in Cancer Prevention, Development and Therapy
Anti-Cancer Agents in Medicinal Chemistry Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy Effect of PI3K/AKT/mTOR Signaling Pathway on Regulating and Controlling the Anti-Invasion and Metastasis of Hepatoma Cells by Bufalin
Recent Patents on Anti-Cancer Drug Discovery Advances of Bioinformatics Applied to Development and Evaluation of Boron-Containing Compounds
Current Organic Chemistry Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Stem cells contributing to postnatal skeletogenesis in the mouse bone marrow
Current Stem Cell Research & Therapy The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews The Role of miR-129-5p in Cancer: A Novel Therapeutic Target
Current Molecular Pharmacology Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies
Current Pharmaceutical Design The Therapeutic Potential of Melatonin in Neurological Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery